aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE) will release its Q1 2022 financial results and provide a corporate update on May 9, 2022, after market close. The management team will host a conference call at 5:00 p.m. EDT to discuss the results and future developments. aTyr Pharma focuses on developing innovative biotherapeutics, particularly through its lead candidate, efzofitimod, which targets the neuropilin-2 receptor involved in fibrotic lung disease. For more details, visit aTyr Pharma's website.

Positive

• Management to provide a corporate update after reporting Q1 2022 results.
• Focus on innovative medicines with a strong intellectual property estate.

Negative

• None.

Management to host conference call and webcast on May 9th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2022 financial results and provide a corporate update after the market close on Monday, May 9, 2022. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Monday, May 9th @ 5:00 p.m. EDT / 2:00 p.m. PDT
Domestic: 844-358-9116
International: 209-905-5951
Conference ID: 9273437
Webcast: http://investors.atyrpharma.com/events-and-webcasts

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

FAQ

What are the financial results expected from aTyr Pharma on May 9, 2022?

aTyr Pharma will report its Q1 2022 financial results on May 9, 2022, after market close.

What is the focus of aTyr Pharma's drug development?

aTyr Pharma focuses on developing biotherapeutics based on novel biological pathways, particularly for fibrotic lung disease.

When will aTyr Pharma's conference call take place?

The conference call is scheduled for May 9, 2022, at 5:00 p.m. EDT.

What is the lead product candidate of aTyr Pharma?

The lead product candidate is efzofitimod, which is designed to downregulate immune engagement in fibrotic lung disease.